D-W. Kim

发表

High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer

Jae Hyun Kim, S. Lee, S. Im, 2008, British Journal of Cancer.

BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase

A. Quintás-Cardama, J. Lipton, G. Saglio, 2015, Leukemia.

High performance and low leakage current InGaAs-on-silicon FinFETs with 20 nm gate length

M. Krishnan, E. Cartier, V. Narayanan, 2017, 2017 Symposium on VLSI Technology.

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

M. Baccarani, R. Clark, G. Rosti, 2016, Leukemia.

Mutation in TET2 or TP53 predicts poor survival in patients with myelodysplastic syndrome receiving hypomethylating treatment or stem cell transplantation

S. Lee, S. Lee, A. Kwon, 2015, Bone Marrow Transplantation.

Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance

R. Larson, M. Baccarani, K. Bhalla, 2013, Leukemia.

PHASE II ACTIVITY OF THE HSP90 INHIBITOR AUY922 IN PATIENTS WITH ALK-REARRANGED (ALK plus ) OR EGFR-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

L. Sequist, E. Smit, E. Felip, 2012 .

First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small cell lung cancer.

A. Jimeno, A. Nagrial, D. Rasco, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone.

Y. Bang, D. Heo, S. Im, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Cobll1 is linked to drug resistance and blastic transformation in chronic myeloid leukemia

H. Kim, S.‐H. Kim, J. Kim, 2017, Leukemia.

Response to combined modality therapy correlates with survival in locally advanced non-small-cell lung cancer.

H. Choy, David H. Johnson, Y. Shyr, 2005, International journal of radiation oncology, biology, physics.

Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy

R. Larson, M. Baccarani, D. Marin, 2010, Leukemia.

Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials

J. Cortes, F. Mahon, N. Shah, 2015, Leukemia.

Safety and Efficacy of Quavonlimab, a Novel Anti-CTLA-4 Antibody (MK-1308), in Combination with Pembrolizumab in First-Line Advanced Non-Small Cell Lung Cancer.

M. Ahn, A. Nagrial, M. Satouchi, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

R. Greil, O. Popovych, C. Gridelli, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Biomarker analysis in stage III–IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival

S. Im, K. Lee, N. Kim, 2009, British Journal of Cancer.

Cleavage of BCR–ABL transcripts at the T315I point mutation by DNAzyme promotes apoptotic cell death in imatinib-resistant BCR–ABL leukemic cells

W. Jung, D-W. Kim, Y-H Cho, 2013, Leukemia.

Imatinib induces a cytogenetic response in blast crisis or interferon failure chronic myeloid leukemia patients with e19a2 BCR-ABL transcripts

S. Lee, Y. Kim, H. Kim, 2004, Leukemia.

Cytogenetic clonal evolution alone in CML relapse post-transplantation does not adversely affect response to imatinib mesylate treatment

S. Lee, Y. Kim, H. Kim, 2004, Bone Marrow Transplantation.

TEMPORARY REMOVAL: Updated overall survival and final progression-free survival data for patients with treatment-naïve advanced ALK-positive non-small-cell lung cancer in the ALEX study.

A. Shaw, S. Ou, T. Mok, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia.

C. Choi, H. Eom, H. Yhim, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study

J. Radich, R. Larson, M. Baccarani, 2013, Leukemia.

Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value

J. Radich, H. Kantarjian, J. Lipton, 2009, Leukemia.

Phase 1/2 study of the safety and clinical activity of durvalumab in patients with non-small cell lung cancer (NSCLC)

S. Ou, M. Ahn, N. Segal, 2016 .

Safety and efficacy of pralsetinib in RET fusion-positive non-small cell lung cancer including as first-line therapy: update from the ARROW trial.

Y. Houvras, A. Mansfield, J. Mazières, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS.

T. Mitsudomi, S. Peters, D. Planchard, 2019, Annals of Oncology.

Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale

D. Colomer, R. Zadro, N. Cross, 2016, Leukemia.

Development and evaluation of a secondary reference panel for BCR-ABL1 quanti ﬁ cation on the International Scale

D. Colomer, R. Zadro, H. White, 2016 .

A certi ﬁ ed plasmid reference material for the standardisation of BCR – ABL1 mRNA quanti ﬁ cation by real-time quantitative PCR

D. Colomer, T. Lion, M. Jansson, 2015 .

Impact of IKZF1 deletions on long-term outcomes of allo-SCT following imatinib-based chemotherapy in adult Philadelphia chromosome-positive ALL

S. Lee, Y. Kim, Y. Kim, 2015, Bone Marrow Transplantation.

Impact of pretransplant red cell transfusion on outcome after allogeneic stem cell transplantation in adult patients with severe aplastic anemia

J. W. Lee, S. Lee, Y. Kim, 2016, Bone Marrow Transplantation.

PBSC vs BM grafts with myeloablative conditioning for unrelated donor transplantation in adults with high-risk ALL

S. Lee, Y. Kim, H. Kim, 2014, Bone Marrow Transplantation.

Preemptive treatment of minimal residual disease post transplant in CML using real-time quantitative RT-PCR: a prospective, randomized trial

S. Lee, Y. Kim, D-W. Kim, 2004, Bone Marrow Transplantation.

Pretransplant imatinib can improve the outcome of nonmyeloablative stem cell transplantation without increasing the morbidity in Philadelphia chromosome-positive chronic myeloid leukemia

J. W. Lee, H. Kim, S. Lee, 2004, Leukemia.

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

I. Flinn, R. Larson, R. Clark, 2012, Leukemia.

Feasibility of NIH consensus criteria for chronic graft-versus-host disease

S. Lee, Y. Kim, H. Kim, 2009, Leukemia.

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.

K. O'Byrne, T. Mok, E. Tan, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Azacytidine treatment after discontinuation of immunosuppressants in patients with myelodysplastic syndrome and relapse after allo-SCT at a single center

S. Lee, Y. Kim, H. Kim, 2010, Bone Marrow Transplantation.

Potential role of adoptively transferred allogeneic WT1-specific CD4+ and CD8+ T lymphocytes for the sustained remission of refractory AML

S. Lee, Y. Kim, H. Kim, 2010, Bone Marrow Transplantation.

Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials

J. Lunceford, M. Ayers, R. Herbst, 2019, Annals of Oncology.

Identification of HLA-B*56 variant (B*560502) in the Korean population.

D-W. Kim, C. Pyo, T. Kim, 2004, Tissue antigens.

Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.

H. Min, D. Heo, Y. Jeon, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

The siRNA cocktail targeting interleukin 10 receptor and transforming growth factor‐β receptor on dendritic cells potentiates tumour antigen‐specific CD8+ T cell immunity

J. Jeon, Soon-Oh Hong, Tae Woo Kim, 2015, Clinical and experimental immunology.

533MO Phase Ib study of BI 836880, a VEGF/Ang2-blocking nanobody®, in combination with BI 754091, an anti-PD-1 antibody: Initial results in patients (pts) with solid tumours

F. Barlesi, F. Ghiringhelli, B. Hackanson, 2020 .

Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study

S. Lee, Y. Kim, H. Kim, 2009, Leukemia.

Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant‐specific inhibitor, in T790M‐positive NSCLC at the recommended phase II dose: 1300

E. Cho, Y. Min, J.-Y. Han, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS

T. Mitsudomi, S. Peters, D. Planchard, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

MA07.09 BBT-176, a 4th generation EGFR TKI, for Progressed NSCLC after EGFR TKI Therapy: PK, Safety and Efficacy from Phase 1 Study

S. Ou, D-W. Kim, T.M. Kim, 2022, Journal of Thoracic Oncology.

1365TiP A phase I/II, open-label study of BBT-176, a triple mutation targeting EGFR TKI, in patients with NSCLC who progressed after prior EGFR TKI therapy

G. Lee, D-W. Kim, S. Lim, 2021, Annals of Oncology.

Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer.

Dong-Wan Kim, D. Heo, S. Shin, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial

K. O'Byrne, T. Mok, E. Tan, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.

P. Jänne, S. Ou, Gregory Riely, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.

D. Planchard, P. Jänne, M. Ahn, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Haplotype mismatched transplantation using high doses of peripheral blood CD34+ cells together with stratified conditioning regimens for high-risk adult acute myeloid leukemia patients: a pilot study in a single Korean institution

Y. Kim, H. Kim, D-W. Kim, 2005, Bone Marrow Transplantation.

1400P Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLC

M. Ahn, D. Rasco, E. Chartash, 2020, Annals of Oncology.

Risk and prognostic factors for acute GVHD based on NIH consensus criteria

Y. Kim, H. Kim, D-W. Kim, 2013, Bone Marrow Transplantation.

Influence of killer cell immunoglobulin-like receptor genotypes on acute graft-vs-host disease after unrelated hematopoietic stem cell transplantation in Koreans.

Y. Kim, D-W. Kim, C. Min, 2007, Tissue antigens.

Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma.

D. Heo, Y. Jeon, Y. Koh, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase (Ph) II study of MBG453 + spartalizumab in patients (pts) with non-small cell lung cancer (NSCLC) and melanoma pretreated with anti–PD-1/L1 therapy

G. Curigliano, A. Santoro, S. Gutzwiller, 2019, Annals of Oncology.

Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial

J. Ahn, M. Ahn, Keunchil Park, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Autologous stem cell transplantation using modified TAM or combination of triple-alkylating agents conditioning regimens as one of the post-remission treatments in patients with adult acute myeloid leukemia in first complete remission

H. Kim, D-W. Kim, W. Min, 2004, Bone Marrow Transplantation.

Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti‐programmed cell death‐ligand‐1 (PD‐L1) antibody, combined with gefitinib (G): A phase I expansion in TKI‐naïve patients (pts) with EGFR mutant NSCLC: 57O

Haiyi Jiang, D. Gibbons, L. Chow, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

LBA3A PHASE I STUDY OF AZD9291 IN PATIENTS WITH EGFR-TKI-RESISTANT ADVANCED NSCLC – UPDATED PROGRESSION FREE SURVIVAL AND DURATION OF RESPONSE DATA

P. Jänne, M. Ahn, D. Planchard, 2015 .

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial.

Y. Shentu, R. Herbst, M. Ahn, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

190TiP: ELUXA 1: Phase II study of BI 1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI).

P. Jänne, S. Ou, Keunchil Park, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

LBA2 Lorlatinib vs crizotinib in the first-line treatment of patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC): Results of the phase III CROWN study

A. Shaw, T. Mok, E. Felip, 2020 .

Brigatinib (BRG) in Asian vs non-Asian patients (pts) with crizotinib (CRZ)-refractory ALK+ NSCLC in the phase II ALTA trial

Edward S. Kim, H. Groen, S. Gettinger, 2019, Annals of Oncology.

1298O_PRAlectinib vs crizotinib in treatment-naïve ALK+ NSCLC: CNS efficacy results from the ALEX study

A. Shaw, S. Ou, T. Mok, 2017 .

Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary: a systematic review and meta-analysis

S. Hahn, S. Rha, S. Rha, 2012, British Journal of Cancer.

LBA55 Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial

P. Jänne, D. Planchard, M. Aregay, 2022, Annals of Oncology.

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial

Y. Shentu, R. Herbst, M. Ahn, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: A multicenter trial of the Korean Cancer Study Group (LU17-19)

D. Heo, B. Keam, C. Ock, 2019, Annals of Oncology.

Experiences of t-PA use in moderate-to-severe hepatic veno-occlusive disease after hematopoietic SCT: is it still reasonable to use t-PA?

S. Lee, Y. Kim, H. Kim, 2013, Bone Marrow Transplantation.

Gene expression signatures associated with the resistance to imatinib

H. K. Kim, S. Ha, H. Namkoong, 2006, Leukemia.

Anti-leukaemic role of acute GvHD after unrelated haematopoietic stem cell transplantation in intermediate- to high-risk acute myelogenous leukaemia

S. Lee, H. Kim, D-W. Kim, 2007, Bone Marrow Transplantation.

A certified plasmid reference material for the standardisation of BCR–ABL1 mRNA quantification by real-time quantitative PCR

H Emons, V Kairisto, S Trapmann, 2014, Leukemia.

Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: Updated results from the phase III ALTA-1L trial

S. Gettinger, M. Ahn, R. Camidge, 2019, Annals of Oncology.

410O_PRAlectinib (ALC) vs crizotinib (CRZ) in treatment-naïve ALK+ non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study

S. Ou, T. Mok, S. Peters, 2017 .

Genetic landscape of patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study.

Serafino Pantano, B. Solomon, D. Camidge, 2021, Lung Cancer.

984P Relationship between RET fusion partner and treatment outcomes in patients (pts) with non-small cell lung cancer (NSCLC) from the phase I/II ARROW study and real-world data (RWD)

J. Mazières, G. Lopes, M. Nowicka, 2022, Annals of Oncology.

1258O Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC

E. Cho, J. Infante, B. Cho, 2020 .

Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial.

S. Gettinger, M. Ahn, D. Camidge, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I study of gefitinib (G) + durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) sensitising mutations.

D. Gibbons, M. Roudier, M. Marotti, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Survival benefits with transplantation in secondary AML evolving from myelodysplastic syndrome with hypomethylating treatment failure

Y. Kim, H. Kim, D-W. Kim, 2013, Bone Marrow Transplantation.

Donor-specific differences in long-term outcomes of myeloablative transplantation in adults with Philadelphia-negative acute lymphoblastic leukemia

S. Lee, Y. Kim, H. Kim, 2010, Leukemia.

Treatment with pralsetinib (formerly BLU-667), a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC)

R. Doebele, G. Curigliano, S. Gadgeel, 2019, Annals of Oncology.

Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): updated results from PROFILE 1001

S. C. Wang, Jeffrey W. Clark, A. Shaw, 2016 .